Apellis has discontinued the development of systemic pegcetacoplan for ALS. Unfortunately the Phase 2 MERIDIAN study did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank scores at Week 52. Systemic pegcetacoplan was generally well tolerated in the study, and the data were consistent with the established safety profile. The full MERIDIAN dataset is being analyzed, and detailed data is expected to be presented at a future medical meeting. For more information please see the press release.
Amyotrophic Lateral Sclerosis (ALS)
Here you can find materials related to Apellis presentations at congresses
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.